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Comparison of PI3K Pathway in HPV-Associated Oropharyngeal
Cancer With and Without Tobacco Exposure
Si-Young Kiessling, MD ; Martina Anja Broglie, MD; Alex Soltermann, Prof;
Gerhard Frank Huber, MD; Sandro Johannes Stoeckli, Prof
Objectives: The aim of the study was to evaluate whether HPV associated OPSCC with tobacco exposure follows a differ-
ent carcinogenic pathway compared to HPV associated OPSCC without tobacco exposure and to investigate its prognostic sig-
nificance. The question was addressed with focus on components of the PI3K pathway.
Methods: 184 patients with newly diagnosed OPSCC treated with curative intent were consecutively enrolled. The
expression level of p16, p53, PI3K, mTOR, and PTEN was assessed by immunohistochemistry and analyzed in relation to the
risk factors HPV status and tobacco exposure.
Results: 94 of 184 (51%) patients were p16 positive, p53 overexpression was detected in 48 of 184 (26%) cases. PI3K
overexpression with 70 of 184 (38%) cases was significantly higher in p16 positive tumors. mTOR overexpression was pre-
sent in 90 of 184 (49%) cases and significantly higher in p16 negative tumors. PTEN loss was found in 42 of 184 (23%)
cases without association to p16 expression. p16 positive OPSCC showed lower rates of p53 expression and mTOR expression
as well as higher rates of PI3K expression irrespective of tobacco exposure. Survival analysis showed a distinct intermediate
survival rate of p16 positive smokers. The markers PI3K, mTOR, and PTEN did not have a significant impact on survival.
Conclusion: HPV associated OPSCC with tobacco exposure follows the same expression level of the PI3K pathway as
HPV associated OPSCC without tobacco exposure. The impaired survival rate of the intermediate risk group cannot be
explained by different expression patterns of PI3K, mTOR, and PTEN.
Key Words: Oropharyngeal cancer, HPV, PI3K, tobacco.
Level of Evidence: 2b
INTRODUCTION
During the last decades infection with high risk
type human papilloma virus (HR-HPV) has emerged as
an important cause for the development of oropharyngeal
squamous cell carcinoma (OPSCC).1,2 HPV-associated
tumors are known to have improved treatment response
and better outcomes.3–8 Possible explanations include
both host-intrinsic factors such as superior performance
status, lower rate of comorbidities, and lower incidence of
second primary tumors, as well as tumor-intrinsic factors
such as distinct genetic pathogenesis and enhanced radia-
tion sensitivity.9
Although the National Comprehensive Cancer Net-
work (NCCN) recommends routine HPV testing in
OPSCC, suggestions for modified treatment depending
on the HPV status are currently lacking, but several
prospective trials underway.10
As HPV-related carcinogenesis differs substantially
from traditional smoking- and alcohol-induced path-
ways, it is crucial to understand the carcinogenic mecha-
nisms of the tumors in order to potentially establish
individualized therapeutic modalities. While HPV-
negative, tobacco- and alcohol-related OPSCC are often
characterized by genetic alterations of the TP53 tumor
suppressor gene,1 HPV-associated OPSCC follow a differ-
ent carcinogenic pathway. HPV-positive tumors usually
harbor the p53 wild-type gene,11,12 and are characterized
by inactivation rather than mutation of p53 and pRb
(retinoblastoma protein) by viral oncoproteins E6 and
E7.13 According to a study by Ang et al.5 and other pub-
lications,14,15 HPV-associated OPSCC with exposure to
tobacco show a risk for tumor progression and disease-
related death which is intermediate between the low-
risk group of HPV-associated OPSCC in non-smokers
and the high-risk group of HPV-negative OPSCC. The
question arises whether this intermediate risk cohort
tumor type is characterized by a carcinogenic pathway
different from the one causative for HPV-associated
OPSCC in non-smokers.
One of the most frequently altered carcinogenic
pathways in cancer16,17 is the PI3K (Phosphoinositid 3
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Kinase) pathway which regulates physiologic cellular pro-
cesses including cell proliferation, differentiation, motility,
metabolism, and apoptosis.18,19 Its central components
PI3K, a key signaling activator, and mTOR (mammalian
target of rapamycin), a key downstream regulator, drive
tumor metastasis by promoting cell motility.17 In contrast,
PTEN (phosphate and tensin homolog), a tumor suppres-
sor gene, acts as a negative regulator of this pathway.10,16
In head and neck squamous cell cancer (HNSCC) this
pathway is mutated in 10% to 30%.1,18,20–22 Due to its fre-
quent activation, investigations about agents targeting
this pathway are of highest interest.23 Of note, HNSCC
with PI3K pathway mutation seem to harbor increased
genomic instability which eventually effects the suscepti-
bility of a targeted therapy.22
Several mutational and immunohistochemical stud-
ies were able to demonstrate that HPV-associated tumors
showed more frequent mutations and alterations of the
PI3K pathway compared to HPV-negative tumors.21,24–26
Therefore, the aim of our study was: (1) to analyze
the immunohistochemical expression patterns of p53
and central components of the PI3K pathway (PI3K,
mTOR, PTEN) in the low-risk group of HPV-associated
OPSCC in non-smokers compared to the intermediate-
risk cohort of HPV-positive smokers and the high-risk
group of HPV-negative OPSCC; and (2) to assess the
impact on survival of these different markers.
MATERIALS AND METHODS
Patients
The total number of 184 consecutive patients treated in
curative intent for a newly diagnosed OPSCC at the University
Hospital of Zurich were evaluated. Tumor tissue from the primary
tumor was collected from all patients at the time of diagnosis. The
treatment modalities included primary radio(chemo)therapy, pri-
mary surgery, or a combined approach consisting of surgery fol-
lowed by adjuvant radio(chemo)therapy. Smoking was defined as
current smoking or a history of more than 10 pack-years not lon-
ger than 10 years ago. Alcohol consumption was defined as the
intake of 3 units of alcohol per day.
Tumors were classified according to the 7th edition (2010)
of the Union Internationale Contre le Cancer (UICC) TNM clas-
sification of malignant tumors.27
Tissue Microarray and Immunohistochemical
Staining
Formalin-fixed and paraffin-embedded tissue of a pretreat-
ment biopsy or a resection specimen was available for all
patients. A tissue microarray (TMA) block was constructed in
order to ensure uniform staining of antibodies. For each patient,
two regions from the core of the tumor were selected for TMA
construction. The preparation of the TMA slides as well as anti-
body staining for p16 as a surrogate marker for HPV-positive
tumors and p53 were performed as previously described.28
For the expression staining analysis of PI3K, mTOR, and
PTEN, following antibodies were used: mouse monoclonal anti-
human PTEN (Dako A/S) diluted 1:100, rabbit monoclonal PI3K
Kinase p110alpha (Cell Signaling Technology) diluted 1:200,
rabbit monoclonal anti phospho-mTOR (Cell Signaling Technol-
ogy) diluted 1:50. The staining intensity was scored from 0 to 2
(05no staining, 15 intermediate staining, 25 strong staining)
for each of the three markers. The sum of the staining score of
the two specimens was used to define the total staining inten-
sity. A PTEN loss was defined as a total staining intensity of 0.
Overexpression of mTOR and PI3K was defined as a sum of the
two scores 2.
Statistical Analysis
A descriptive analysis was performed by cross tables and
Fishers exact test to calculate significant differences and corre-
lations between immunohistochemical and clinical parameters.
Categorial variables were compared using a Chi-square test.
Survival analyses for overall survival (OS), and disease-
specific survival (DSS) were performed by Kaplan Meier curves.
To compare different risk groups, a log rank test was used. Uni-
variate and multivariate analysis using cox proportional hazard
models to identify the impact of different risk factors on sur-
vival were outlined. A P-value of .05 was considered statisti-
cally significant. All statistical analyses were calculated with
SPSS (Version 22).
RESULTS
Expression Status in Entire Cohort
A total of 184 consecutive patients with OPSCC
were included with a male to female ratio of 3.6:1 (78%
vs. 22%). The median age was 60 years and ranged from
42 to 91 years. 94 of 184 (51%) of the patients had a
p16-positive tumor. P53 overexpression was detected in
48 of 184 (26%) cases. PI3K overexpression was detected
in 70 of 184 (38%), mTOR overexpression in 90 of 184
(49%), and PTEN loss in 42 of 184 (23%) cases.
Expression Status in p16-Related Groups
P53 overexpression was significantly more often
present in p16-negative compared to p16-positive
tumors. PI3K overexpression was significantly higher in
p16 positive tumors whereas mTOR overexpression was
more frequent in p16 negative tumors. PTEN loss was
not significantly different in the two groups (Table I).
Expression Status in p16 and Smoking-Related
Subgroups
Expression of p53, PI3K, mTOR, and loss of PTEN
were analyzed in three subgroups according to p16
expression and smoking status. Subgroups were defined
as A5p16-positive non-smokers, B5p16-positive smok-
ers, and C5p16 negative. The characteristics of the sub-
groups and the results are given in Table II.
TABLE I.
Correlation of Antibodies and p16 Status
p16-positive
(n5 94)
p16-negative
(n5 90) P-value
PI3K overexpression 44 (63%) 26 (29%) .02*
mTOR overexpression 36 (40%) 54 (60%) .005*
PTEN loss 22 (23%) 20 (22%) .86
P53 positive 8 (8%) 40 (44%) <.001
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P53 overexpression was significantly more often
present in the p16-negative subgroup C compared to
both p16-positive subgroups A and B. The presence of
the risk factor smoking did not have an impact on p53
overexpression in the p16-positive subgroup.
PI3K was comparably overexpressed in both p16-
positive subgroups A and B irrespective of the risk factor
smoking. In contrast, the expression rate was signifi-
cantly lower in the p16-negative subgroup C. An overex-
pression of mTOR was significantly more often detected
in the p16-negative subgroup C compared to the p16-
positive subgroups A and B. No significant difference
was seen between the two p16-positive subgroups A and
B. PTEN loss was a rare event and occurred at a compa-
rably low frequency in all three subgroups.
Survival Analysis in Entire Cohort
The median observation time was 61 months (range
6 to 144 months). A total of 68 of 184 (37%) patients
died, 45 of 68 (66%) died of disease and 23 of 68 (35%) of
other causes. The 5-year overall survival (OS) and dis-
ease specific survival (DSS) rates in the entire cohort
were 69% and 82%, respectively.
In the Kaplan-Meier analysis, p16 overexpression had
a favorable impact on OS (78% vs. 59% P5.001) and DSS
(84% vs. 66% P5.001). In contrast, p53 was a poor prognos-
tic marker for OS (10% vs. 77% P5<.001) and DSS (26%
vs. 83% P5.001). mTOR overexpression was a negative pre-
dictor for OS (58% vs. 77%, P5.02) but not for DSS (68% vs.
83%, P5.07). PI3K overexpression did not have prognostic
impact on OS (70% vs. 67%, P5.7) or DSS (81% vs. 74%,
P5.16). PTEN loss did not influence OS (49% vs. 73%,
P5.17) and DSS (77% vs. 81%, P5.48). Other factors with
prognostic impact were T- and N-category as well as treat-
ment modality whereas gender, age, smoking, and alcohol
intake did not affect the survival rates (data not shown).
In univariate analysis based on cox regression
model, p16 overexpression showed a favorable impact on
OS (OS HR 0.42 95% CI 0.25–0.69, P5.001) and DSS
(DSS HR 0.37 95% CI 0.19–0.70, P5.001). In contrast,
p53 overexpression was a negative predictor for OS (OS
HR 2.33 95% CI 1.43–3.77, P5.001) and DSS (DSS HR
2.63 95% CI 1.46–4.75, P5.002). mTOR overexpression
revealed a negative impact on OS (OS HR 1.81 95% CI
1.10–2.95, P5.01), but not on DSS (DSS HR 1.72 95%
CI 0.95–3.13, P5.07). PI3K overexpression and PTEN
loss did not play a prognostic role for OS and DSS (PI3K
OS HR 0.91 95% CI 0.55–1.49, P5.7; DSS HR 0.64 95%
CI 0.34–1.19, P5.15) (PTEN loss OS HR 0.65 95% CI
0.35–1.21, P5.15; DSS HR 0.78 95% CI 0.37–1.59,
TABLE II.
Subgroup Analysis in Different Risk Groups According to p16 Expression and Tobacco Exposure
p16-pos-nonsmoking
(A) n5 44
p16-pos-smoking
(B) n5 50
p16-neg
(C) n5 90
P-value
A vs. B vs. C A vs. B B vs. C A vs. C
PI3K overexpression
No PI3K overexpression
22 (50%)
22 (50%)
22 (44%)
27 (54%)
26 (29%)
61 (68%)
.05* .62 .08 .02*
mTOR overexpression
No mTOR overexpression.
17 (39%)
26 (59%)
19 (38%)
28 (56%)
54 (60%)
33 (37%)
.01* .93 .02* .02*
PTEN loss
No PTEN loss
11 (25%)
33 (75%)
11 (22%)
39 (78%)
20 (22%)
70 (78%)
.82 .59 .99 .56
Mean age (range 42-91) 62.4 61.5 60.3 .47 .45 .46 .46
Gender M
F
36 (82%)
8 (18%)
41 (82%)
9 (18%)
67 (74%)
23 (26%)
.47 .98 .31 .34
T-category T1/T2
T3/T4
32 (73%)
12 (27%)
32 (64%)
18 (36%)
44 (49%)
46 (51%)
.02* .37 .08 .01*
N-category N0/N1/N2a
N2b/N2c/N3
15 (34%)
29 (66%)
18 (36%)
32 (64%)
36 (40%)
54 (60%)
.77 .85 .64 .51
Site Tonsil
Base of tongue
Other
34 (77%)
10 (13%)
0 (0%)
36 (72%)
14 (28%)
0 (0%)
56 (62%)
27 (30%)
4 (4%)
.18 .56 .22 .17
Alcohol >3U
<3U
6 (14%)
38 (86%)
21 (42%)
29 (58%)
46 (51%)
44 (49%)
<.01* <.01* .3 <.01*
Second cancer Yes
No
6 (4%)
38 (86%)
8 (16%)
42 (84%)
21 (23%)
69 (77%)
.33 .75 .31 .19
p53 Positive
Negative
4 (9%)
40 (91%)
4 (8%)
46 (92%)
40 (44%)
50 (56%)
<.01* .85 <.01* <.01*
Therapy Surgery
Radiotherapy
Surgery1RT
7 (16%)
20 (45%)
17 (39%)
3 (6%)
29 (58%)
18 (36%)
12 (13%)
63 (70%)
15 (17%)
.01* .23 .02* .01*
U5 unit; RT5radiotherapy.
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P5.47). T- and N-category were prognostic parameters
for DSS, whereas therapy modality could reach signifi-
cance only for OS (P5.05) and not for DSS (P5.06). Fur-
ther parameters such as smoking, alcohol intake, gender,
and age did not influence survival (Tables III and IV).
In multivariate cox regression model, only p53 over-
expression kept its negative prognostic significance
whereas the other factors such as p16 overexpression
(P5.06) and mTOR overexpression (P5.12) lost its prog-
nostic impact. After adding T-, N-category, smoking,
alcohol, PTEN loss, and PI3K in the multivariate cox
regression analysis, these parameters also did not have
prognostic influence (Tables III and IV).
Survival Analysis in Risk-Related Subgroups
The 5-year OS for p16-positive non-smokers (Group
A), p16-positive smokers (Group B), and p-16 negative
patients (Group C) were 83%, 72%, and 58%,
respectively (P5.001) (Fig.1). There was no significant
difference between Groups A and B (P5.19) but between
Group B and C (P5.03) and Group A and C (P5.001).
Similar results were observed for 5-year DSS (Group A
88%, Group B 81%, and Group C 66%, P5.006) (Fig 2)
with a significant difference between Groups B and C
(P5.02) and Groups A and C (P5.008) but not Groups
A and B (P5.66).
In Kaplan Meier analysis, there were no important
prognosticators of the tested markers p53, PI3K, mTOR,
or PTEN loss in subgroups A to C. Same results could
be demonstrated in univariate analysis.
Further parameters such as gender, T-status and
therapy modality did also not show a prognostic impact
on OS and DSS in the subgroups A, B, and C.
DISCUSSION
HR-HPV related OPSCC go along with a particular
tumor biology and risk profile when compared to HPV-
TABLE III.
Univariate and Multivariate Analysis of Overall Survival for Patients with OPSCC. (Therapy modality was divided in 3 groups as in Table II.
T- and N- category are defined as in Table II.)
Parameters
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
p16 positivity 0.42 (0.25–0.69) .001* 0.59 (0.32–1.10) .09
p53 positivity 2.33 (1.43–3.77) .001* 1.83 (1.04–3.22) .03*
PI3K overexpression 0.91 (0.55–1.49) .7 0.87 (0.50–1.48) .61
mTOR overexpression 1.81 (1.10–2.95) .01* 1.13 (0.62–2.04) .67
PTEN loss 0.65 (0.35–1.21) .15 0.68 (0.34–1.37) .28
Smoking 1.59 (0.92–2.76) .96 1.07 (0.56–2.05) .83
Alcohol 1.27 (0.78–2.05) .32 0.98 (0.56–1.71) .94
T-category 1.31 (1.05–1.63) .01* 1.25 (0.96–1.63) .09
N-category 1.16 (0.97–1.38) .09 1.18 (0.99–1.41) .06
Therapy modality 0.67 (0.45–1.00) .05* - -
Gender (male) 1.30 (0.73–2.30) .36 - -
Age (>60y) 1.02 (1.00–1.05) .02* - -
TABLE IV.
Univariate and Multivariate Analysis of Disease-Specific Survival for Patients with OPSCC. (Therapy modality was divided in 3 groups as in
Table II. T- and N- category are defined as in Table II.)
Parameters
Univariate analysis Multivariate analysis
HR (95% CI) P-value HR (95% CI) P-value
p16 positivity 0.42 (0.25–0.69) .001* 0.53 (0.25–1.14) .10
p53 positivity 2.33 (1.43–3.77) .001* 1.88 (0.94–3.75) .07
PI3K overexpression 0.91 (0.55–1.49) .7 0.67 (0.37–1.33) .26
mTOR overexpression 1.81 (1.10–2.95) .01* 0.85 (0.43–1.70) .66
PTEN loss 0.65 (0.35–1.21) .15 0.80 (0.37–1.76) .59
Smoking 1.59 (0.92–2.76) .96 0.92 (0.42–2.00) .84
Alcohol 1.27 (0.78–2.05) .32 1.49 (0.77–2.87) .23
T-category 1.31 (1.05–1.63) .01* 1.51 (1.09–2.10) .01*
N-category 1.16 (0.97–1.38) .09 1.42 (1.13–1.78) .002*
Therapy modality 0.67 (0.45–1.00) .05* - -
Gender (male) 1.30 (0.73–2.30) .36 - -
Age (>60y) 1.02 (1.00–1.05) .02* - -
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negative, smoking-, and alcohol-induced OPSCC.29–31
HPV-positivity is an independent and strong risk factor
associated with improved survival of OPSCC patients.32
The oncogenic proteins E6 and E7 are consistently
expressed in HPV-associated cancer targeting the retino-
blastoma (RB1) and TP53 tumor suppressor net-
works,33–37 while smoking- and alcohol-induced, HPV-
negative tumors harbor genetic alterations of the TP53
gene.38 Beside the low-risk group of HPV-associated
OPSCC in non-smokers and the high-risk group of HPV-
negative OPSCC there exists a group of HPV-associated
OPSCC with exposure to tobacco and alcohol. According
to recent studies this group shows an intermediate risk
profile5,15,39 in relation to survival outcomes. The exact
carcinogenic pathway of this intermediate-risk tumor
type has not been investigated so far and the question
arises if the intermediate risk OPSCC rather follows the
pathway of HPV-associated or that of HPV-negative
OPSCC.
The PI3K pathway is a major regulator in tumori-
genesis of head and neck squamous cell cancer (HNSCC)
with mutations in 10% to 30%.1,18,20–22 This pathway is
frequently altered in OPSCC, in particular in HPV-
associated tumors.21,40,41 The exact molecular interaction
between an activated PI3K pathway and the HPV-
associated carcinogenesis is poorly understood.
Beside mutational analyses of genetic alterations of
the PI3K pathway in OPSCC a high correlation of
immunohistochemical expression of signaling molecules
of the PI3K pathway with genetic alterations has been
demonstrated in recent studies.42,43 Because of its cost
and time efficacy and proven strong correlation to DNA
mutation analysis also in other cancer types,44–46 this
method was used in our study.
Therefore, the aim of our study was to assess the
immunohistochemical expression pattern of p53 as sur-
rogate marker for a tobacco-induced cancer pathway and
p16 as surrogate marker for a HPV-induced cancer path-
way as well as the central components of the PI3K sig-
nalling pathway PI3K, mTOR, and PTEN to compare
the pattern between the low-, intermediate-, and high-
risk groups of OPSCC. In addition, the prognostic
impact of these markers on survival has been addressed.
Overall, the p16-positive group revealed signifi-
cantly higher PI3K overexpression and a significantly
lower mTOR overexpression compared to the p16-
negative group. In studies by Won et al. and Chun et al.
no correlation of PI3K and mTOR expression with HPV
status, but a more frequent PTEN expression in HPV-
associated tumors was found.42,43 However, compared to
our study, the number of patients included in both stud-
ies was smaller, possibly explaining the contradictory
results. As PTEN acts as a negative regulator in the
PI3K pathway, loss of PTEN rather than overexpression
seems to have a clinical significance. Therefore, in our
study PTEN loss was assessed with no difference
between the groups. Mutational studies have demon-
strated more prevalent alterations and mutations of
downstream signalling genes of the PI3K pathway in
HPV-associated OPSCC41,47,48 supporting our results.
The expression pattern of PI3K, mTOR, and PTEN was
quite heterogenous. Our data underline the fact that
downstream molecules are not simultaneously upregu-
lated. In the report by Won et al., expression status of
each marker (PI3K, mTOR, AKT, PTEN) did not show a
homogenous pattern either.43 The same results have
been already described in lung and gastric cancer.45,49 It
should be taken into account that our study assessed
expression and not activity of the markers, which does
not necessarily go along. Measurement of other down-
stream effectors of the PI3K pathway such as pS6 or
4EBP1 would potentially allow to analyze pathway
activity.
The division of our cohort into three different risk
groups according to p16 overexpression and the risk fac-
tor smoking5,28 showed as expected significant survival
differences in favor of p16-positive non-smokers.50,51
To the best of our knowledge this is the first study
investigating the above mentioned expression patterns
in the three risk groups based on the HPV positivity and
tobacco exposure.
P53 and mTOR overexpression were significantly
more often present in the p16-negative subgroup,
Fig. 1. Overall survival of p16 positivity and smoking-related risk
groups
Fig. 2. Disease specific survival of p16 positivity and smoking-
related risk groups
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whereas PI3K overexpression was more predominant in
both p16-positive groups irrespective of tobacco expo-
sure. In conclusion, p16-positive OPSCC in smokers
show the same immunohistochemical expression pat-
terns and seem to follow the same carcinogenic pathway
as p16-positive OPSCC in non-smokers. The impaired
survival rates of the intermediate risk group compared
to the p16-positive non-smokers can therefore not be
explained by different expression patterns of PI3K path-
way molecules but rather by smoking-associated second
primary tumors and comorbidities.
Deriving therapeutic consequence based on our
result is preliminary, as the cohort is rather small. Our
results suggest that patients with HPV-associated
OPSCC could benefit from the same targeted therapies
irrespective of smoking status. Clinical trials have to
prove, if differences in mutational status and marker
expression translate into different outcomes. It has been
shown in a study that a PI3K inhibitor (Alpelisib) shows
the same response rate independent of the mutation
status.52
In univariate survival analysis neither PTEN loss
nor PI3K overexpression were prognostic, whereas
mTOR expression was shown to be a negative prognosti-
cator. However, this significance was lost in multivariate
analysis. A recent study by Garcıa-Carracedo et al.
found significant better disease specific survival in
patients with p-s6 expression, a surrogate marker of
mTOR1 activity, in laryngeal cancer.20 Nevertheless,
none of their tested proteins of the PI3K pathway
(PDK1, PTEN, p-AKT, p-s6) had a prognostic signifi-
cance on survival for OPSCC. Neither in breast can-
cer, gastric cancer, or renal cell cancer, expression
status of the PI3K pathway revealed a prognostic
impact.46,49,53
The limitation of our study is that HPV-positivity of
the tumor was only based on p16 overexpression instead
of HPV-DNA or HPV-RNA detection by either polymer-
ase chain reaction (PCR) or in situ hybridization (ISH).
Numerous studies have demonstrated a high correlation
between HPV and p16 expression status in
HNSCC5,15,54–56 and stated that p16 is a reliable bio-
marker of HPV-associated HNSCC. Moreover p16 over-
expression has recently been introduced into TNM
staging.57 In addition, p53 activity was assessed by
immunohistochemistry and not by mutational status
which might yield further information on p53 activity.
CONCLUSION
Based on our results it seems that HPV-associated
OPSCC in smokers show the same expression pattern of
key molecules of the PI3K pathway as HPV-associated
OPSCC in non-smokers. The impaired survival rates of
the intermediate risk group compared to HPV-positive
non-smokers can probably not be explained by different
expression patterns of key molecules of the PI3K path-
way but might be associated with other factors like sec-
ond primary tumors and comorbidities in smokers.
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